black box warning semaglutide FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain FDA warns about safety of

Insulin resistance and PCOS: Patients with severe insulin resistance or polycystic ovary syndrome (PCOS) may have a more complex metabolic profile that requires additional intervention beyond GLP-1 therapy alone

The combined GLP-1 and GIP receptor activation has been examined recently as a promising therapeutic concept, given that the two incretins can act on pancreatic beta cells both synergistically and complementarily through distinct metabolic effects [7]

But that's not the real cost for most people

Chronic stimulation may lead to C-cell hyperplasia and eventual tumor formation

Ongoing Monitoring and Support Medical weight loss requires follow-through